Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Objectives:
To evaluate the safety and effectiveness of cell therapy using precision cells to treat
Advanced Lung Cancer.
Eligibility:
Individuals greater than or equal to 18 years of age and less than or equal to 65 years of
age who have been diagnosed with Advanced Lung Cancer.